Sun Yat-sen University: Brain Neoplasms trials

The registry lists 21 Brain Neoplasms studies with Sun Yat-sen University as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 2 12Phase 3 7No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain MetastasesRecruitingNCT07481786Phase 3
• A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)Not yet recruitingNCT06684873Phase 2
• Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain MetastasisRecruitingNCT06582940Phase 2
• Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain MetastasesRecruitingNCT05768490Phase 3
• Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain MetastasesCompletedNCT05807893Phase 2/3
• Combination of Local Therapy and Target Therapy for Brain Metastases With EGFR MutationStatus unknownNCT05616377
• Treatments for Brain Metastases With Poor Prognostic FactorsStatus unknownNCT05609162
• Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain MetastasesStatus unknownNCT05207904Phase 2
• MR-Linac Guided Adaptive FSRT for Brain Metastases From Non-small Cell Lung CancerCompletedNCT04946019Phase 2
• Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLCCompletedNCT04507217Phase 2
• GM1 Prophylaxis for WBRT Related Cognitive DysfunctionTerminatedNCT04395339Phase 3
• Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLCCompletedNCT04345146Phase 2
• Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in ChinaStatus unknownNCT04334330Phase 2
• Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung CancerStatus unknownNCT04213170Phase 2
• Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLCStatus unknownNCT04211090Phase 2
• A Study of the Gene Mutation Status in Cerebrospinal Fluid, Blood and Tumor Tissue of Non-small Cell Lung Cancer Patients With Brain MetastasesStatus unknownNCT03257735
• A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain MetastasesStatus unknownNCT02832635Phase 2
• EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLCStatus unknownNCT02714010Phase 3
• IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain MetastasesTerminatedNCT02556593Phase 2
• Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung CancerCompletedNCT01951482Phase 3
• Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung CancerStatus unknownNCT01951469Phase 3